Genmab A/S (GMAB)

Etorro trading 970x250
Genmab A/S (GMAB) Logo

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company’s products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson’s disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. Address: Kalvebod Brygge 43, Copenhagen, Denmark, 1560

Genmab A/S News and around…

Latest news about Genmab A/S (GMAB) common stock and company :

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
19 Oct, 2021 Yahoo! Finance

Company Announcement Net sales of DARZALEX® in the third quarter of 2021 totaled USD 1,580 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 19, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were U

Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy
15 Oct, 2021 Yahoo! Finance

Media ReleaseCopenhagen, Denmark, October 15, 2021 Janssen-Cilag International NV (Janssen) received a positive CHMP opinion recommending conditional marketing authorization of amivantamab in Europe for the treatment of adult patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations, after failure of platinum-based therapyRepresents First CHMP opinion for a DuoBody® product candidate Genmab A/S (Nasdaq: GMAB) announced today th

Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
14 Oct, 2021 Yahoo! Finance

Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

Grant of Restricted Stock Units and Warrants to Employees in Genmab
07 Oct, 2021 Yahoo! Finance

Company Announcement COPENHAGEN, Denmark; October 7, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 18,689 restricted stock units and 21,537 warrants to employees of the company and three of the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
01 Oct, 2021 FinancialContent

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug ...

Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
01 Oct, 2021 FinancialContent

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several investigational therapies and technologies in the company’s solid tumor product pipeline will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), being held in Washington, DC, and virtually, November 10-14. The presentations will include a mini-oral session featuring the results of the first-in-human (FIH) phase 1/2 trial evaluating the safety and initial clinical activity of the investigational bispecific antibody, DuoBody®-CD40×4-1BB (GEN1042), in patients with advanced solid tumors. Data from another FIH phase 1/2a trial, evaluating the investigational bispecific antibody, DuoBody®-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumors, will be presented as a poster. In addition, four posters will be presented, including one evaluating DuoBody®-CD3xB7H4 (GEN1047), an investigational therapy in Genmab’s early-stage solid tumor product pipeline.

Genmab Sees RS Rating Improve To 74
01 Oct, 2021 FinancialContent

Genmab shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Stock Upgrades: Genmab Shows Rising Relative Strength
23 Sep, 2021 FinancialContent

Genmab shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Capital Increase in Genmab as a Result of Employee Warrant Exercise
21 Sep, 2021 Yahoo! Finance

Company Announcement COPENHAGEN, Denmark; September 21, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 3,969 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 1,800 shares at DKK 337.40,1,875 shares at DKK 939.50,144 shares at DKK 1,145.00, and150 shares at DKK 1,210.0

Why Genmab's Stock Is Trading Higher Today
21 Sep, 2021 FinancialContent

GenmabA/S (NASDAQ:GMAB)shares are trading higher after the company, along with Seagen Inc. (NASDAQ: SGEN), announced the FDA ...

Why Seagen's Stock Is Trading Higher Today
21 Sep, 2021 FinancialContent

Seagen(NASDAQ:SGEN)shares are trading higher after the company, along with Genmab A/S (NASDAQ: GMAB), announced the FDA has ...

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer
21 Sep, 2021 FinancialContent

TheFDA handed an accelerated approvaltoSeagen Inc(NASDAQ: SGEN) andGenmab A/S’(NASDAQ: ...

Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
20 Sep, 2021 FinancialContent

Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is approved under the FDA’s Accelerated Approval Program based on tumor response and the durability of the response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.1

Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
20 Sep, 2021 FinancialContent

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is approved under the FDA’s Accelerated Approval Program based on tumor response and the durability of the response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.1

Genmab, Seagen, Lennar, SmileDirect See After-Hours Moves
20 Sep, 2021 Yahoo! Finance

Genmab and Seagen said they won accelerated FDA approval for a cervical cancer treatment the companies developed together. "We are pleased with the accelerated approval of TIVDAK, Seagen's third FDA-approved antibody-drug conjugate, and fourth approved medicine," said Roger Dansey, M.D., chief medical officer of Seagen, in the statement. "TIVDAK's approval as a monotherapy in the U.S. is an important milestone for women with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, as they are in need of a new treatment option," Jan van de Winkel, Genmab's CEO, said in the statement.

Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
20 Sep, 2021 FinancialContent

Seagen Inc(NASDAQ: SGEN) andGenmab A/S(NASDAQ: GMAB) haveinterim data from twoPhase 1b/2 innovaTV 205 ...

Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
19 Sep, 2021 FinancialContent

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today presented interim data from two cohorts of the phase 1b/2 innovaTV 205 multi-cohort, open-label trial of tisotumab vedotin in recurrent or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 as part of a featured mini oral presentation. Initial results from these two dose expansion cohorts of the study showed encouraging and durable anti-tumor activity with tisotumab vedotin in combination with carboplatin (Cohort D) as first-line therapy for patients with advanced cervical cancer who had not received prior systemic therapy, with a 55% objective response rate (ORR) and with tisotumab vedotin in combination with pembrolizumab (Cohort F) for patients with advanced cervical cancer who experienced disease progression after 1-2 lines of prior systemic therapy, with a 38% ORR. Both combinations demonstrated a manageable and acceptable safety profile, with no new safety signals identified.

Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
19 Sep, 2021 Yahoo! Finance

Media Release Tisotumab Vedotin in Combination with Carboplatin Showed Encouraging, Durable Anti-Tumor Activity as First-Line Treatment Tisotumab Vedotin in Combination with Pembrolizumab Showed Encouraging, Durable Anti-Tumor Activity in Previously Treated Patients COPENHAGEN, Denmark, and BOTHELL, Wash.; September 19, 2021 - Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today presented interim data from two cohorts of the Phase 1b/2 innovaTV 205 multi-cohort, open-label trial of tis

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2021
16 Sep, 2021 FinancialContent

Upgrades For Signet Jewelers Ltd (NYSE:SIG), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. ...

AbbVie (ABBV) and Genmab Announced The Lancet Published The Results Of The Dose Escalation
09 Sep, 2021 FinancialContent
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
09 Sep, 2021 FinancialContent

Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). The full manuscript is available on The Lancet’s website. Epcoritamab is being co-developed by Genmab and AbbVie.

Moderna stock extends rally after price target gets a 77% boost at Morgan Stanley
07 Sep, 2021 FinancialContent

Shares of Moderna Inc. rallied toward a fifth straight gain Tuesday, after Morgan Stanley analyst Matthew Harrison added nearly $150 to his price target on an increased outlook for the biotechnology company's COVID-19 vaccine sales.

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021
07 Sep, 2021 FinancialContent

Upgrades BMO Capital upgraded the previous rating for BRP Inc (NASDAQ:DOOO) from Market Perform to Outperform. For the ...

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
03 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference
27 Aug, 2021 Yahoo! Finance

Media ReleaseCopenhagen, Denmark, 27 August, 2021 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference at 8:00 AM EDT / 2:00 PM CEST on September 9, 2021. A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content About

Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2021
24 Aug, 2021 FinancialContent

Upgrades Canaccord Genuity upgraded the previous rating for Precision Drilling Corp (NYSE:PDS) from Hold to Buy. For the ...

The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
24 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Highs On Friday
20 Aug, 2021 FinancialContent

Before 10 a.m. ET on Friday, 52 companies hit new 52-week highs. Highlights: Microsoft (NASDAQ:MSFT) was ...

Genmab Stock Flashes Healthy RS Rating
18 Aug, 2021 Yahoo! Finance

When putting together your watchlist, focus on stocks with an 80 or higher RS Rating. Genmab just cleared that benchmark with an upgrade from 79 to 82. Is Genmab stock on your radar? When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

Genmab A/S (GMAB) is a NASDAQ Common Stock listed in , ,

970x250